Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target
Oppenheimer将seres therapeutics评级下调至表现级别,从超越级别中移除了4美元的价格目标。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册